ScholarIQanswers from OpenAlex & ORCID
Marcus Schmidt
ResearcherPublications, citations & collaboration network
Marcus Schmidt is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Marcus Schmidt have?
ScholarIQindexed works
Marcus Schmidt has 634 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Marcus Schmidt have?
ScholarIQcitation count
Marcus Schmidt has 21,316 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Marcus Schmidt?
ScholarIQh-index
Marcus Schmidt has an h-index of 65 in OpenAlex.
What is the i10-index of Marcus Schmidt?
ScholarIQi10-index
Marcus Schmidt has an i10-index of 219 in OpenAlex.
What is the ORCID of Marcus Schmidt?
ScholarIQorcid
The ORCID for Marcus Schmidt is on the source record.
What is the OpenAlex record for Marcus Schmidt?
ScholarIQopenalex
The OpenAlex for Marcus Schmidt is on the source record.
What are the most-cited papers on Marcus Schmidt?
ScholarIQmost cited works
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert, Gϋnter von Minckwitz, Jan C. Brase, Bruno V. Sinn, Stephan Gade, Ralf Kronenwett, Berit M. Pfitzner, Christoph Salat, Sherene Loi, Wolfgang Schmitt, Christian Schem, Karin Fisch, Silvia Darb‐Esfahani, Keyur Mehta, Christos Sotiriou, Stephan Wienert, Peter Klare, Fabrice André, Frederick Klauschen, Jens‐Uwe Blohmer, Kristin Krappmann, Marcus Schmidt, Hans Tesch, Sherko Kümmel, Hans‐Peter Sinn, Christian Jackisch, Manfred Dietel, Toralf Reimer, Michael Untch, Sibylle Loibl
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
David Miles, Joseph Gligorov, Fabrice André, David Cameron, Andreas Schneeweiß, Carlos H. Barrios, Binghe Xu, Andrew Wardley, Diego Kaen, Livia Andrade, Semiglazov Vf, Mattea Reinisch, Shilpen Patel, Monika Patre, L. Morales, Sipahee Lal Patel, Manika Kaul, Teresa Barata, Joyce O’Shaughnessy, Q. Zhang, Binghe Xu, Zhimin Shao, Xiangyu Wang, Cuizhi Geng, Xingchen Yan, Zhongsheng Tong, Kunwei Shen, Yongmei Yin, Tao Sun, James Chih‐Hsin Yang, J Feng, Min Yan, Yan Wang, Qiang Liu, S. Zhang, Michelino De Laurentiis, Armando Santoro, Valentina Guarneri, Marco Colleoni, Clara Natoli, Laura Cortesi, Sabino De Placido, Lorenzo Gianni, Francesco Ferraù, Lorenzo Livi, Alberto Zambelli, Lucia Del Mastro, Giuseppe Tonini, Filippo Montemurro, Giulia Bianchi, R. Pedersini, Salvatore A. Del Prete, Giacomo Allegrini, Giuseppe Naso, Patrizia Vici, D. Loirat, Audrey Mailliez, Franck Priou, Olivier Trédan, F. Dalenc, Christophe Perrin, Joseph Gligorov, Morales-Pancorbo David, Nadine Dohollou, Luís Teixeira, Fabien Brocard, Antoine Arnaud, Suzette Delaloge, Jean‐Philippe Spano, Luigi Mansi, Livia Andrade, Fernanda Damian, José Luiz Pedrini, Sandra M. Aleixo, Roberto Hegg, R. Junior, Mattea Reinisch, Marcus Schmidt, C. Wenzel, E.‐M. Grischke, Andreas Schneeweiß, Marianne Just, Nadia Harbeck, Claudia Schumacher, Ubong Peters, Dorothea Fischer, Helmut Forstbauer, Rüdiger Liersch, Ellen Warner, Nathaniel Bouganim, C. T. Doyle, Julie Price Hiller, Ted Vandenberg, Michel Pavic, Andrew Robinson, Gloria Roldan Urgoiti, Nadia Califaretti, Ahmet Alacacıoğlu, M. Gumus, Bülent Yalçın
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
Martin Filipits, Margaretha Rudas, R. Jakesz, Peter Dubsky, Florian Fitzal, Christian F. Singer, Otto Dietze, Richard Greil, Andrea Jelen, P. Sevelda, Christa Freibauer, Volkmar Müller, F. Jänicke, Marcus Schmidt, H. Kölbl, Achim Rody, Manfred Kaufmann, Werner Schroth, Hiltrud Brauch, Matthias Schwab, Péter Fritz, Karsten E. Weber, Inke Sabine Feder, Guido Hennig, Ralf Kronenwett, Mathias Gehrmann, Michael Gnant
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Carsten Denkert, Fenja Seither, Andreas Schneeweiß, Theresa Link, Jens‐Uwe Blohmer, Marianne Just, Pauline Wimberger, A Forberger, Hans Tesch, Christian Jackisch, Sabine Schmatloch, Mattea Reinisch, Erich Solomayer, Wolfgang Schmitt, Claus Hanusch, Peter A. Fasching, Kristina Lübbe, Christine Solbach, Jens Huober, Kerstin Rhiem, Frederik Marmé, Toralf Reimer, Marcus Schmidt, Bruno V. Sinn, Wolfgang Janni, Elmar Stickeler, Laura L. Michel, Oliver Stötzer, Eric Hahnen, Jenny Furlanetto, Sabine Seiler, Valentina Nekljudova, Michael Untch, Sibylle Loibl
A clinically relevant gene signature in triple negative and basal-like breast cancer
Achim Rody, Thomas Karn, Cornelia Liedtke, Lajos Pusztai, Eugen Ruckhaeberle, Lars Hanker, R. Gaetje, Christine Solbach, A. Ahr, Dirk Metzler, Marcus Schmidt, Volkmar Müller, Uwe Holtrich, Manfred Kaufmann